The invention relates to crystalline forms of 4-((R)-2-{[6-((S)-3-methoxy-pyrrolidin-1-yl)-2-phenyl-pyrimidine-4‑carbonyl]-amino}-3-phosphono-propionyl)-piperazine-1-carboxylic acid butyl ester hydrochloride, processes for the preparation thereof, pharmaceutical compositions comprising said crystalline forms, pharmaceutical compositions prepared from such crystalline forms and their use as a medicament, especially as a P2Y12receptor antagonist.本發明係關於4-((R)-2-{[6-((S)-3-甲氧基-吡咯啶-1-基)-2-苯基-嘧啶-4-羰基]-胺基}-3-膦醯基-丙醯基)-六氫吡嗪-1-甲酸丁基酯鹽酸鹽之結晶型式；製備其之方法；包含該等結晶型式之醫藥組合物；自該等結晶型式製備之醫藥組合物；及其作為藥劑、尤其作為P2Y12受體拮抗劑之用途。
